Contextual Reprogramming of CAR-T Cells for the Treatment of HER2-Expressing Cancers

Combining checkpoint inhibition (CPI) to adoptive cell therapy (ACT) may prevent engineered chimeric antigen receptor (CAR)-T cell exhaustion and improve outcomes. However, cumulative toxicities and costs limit this approach.